Travere Therapeutics (TVTX) Assets Average (2011 - 2026)

Travere Therapeutics has reported Assets Average for 16 years, with the latest figure at $580.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 1.53% year-over-year to $580.2 million; the trailing twelve-month figure through Mar 2026 stood at $580.2 million (up 1.53% YoY), and the FY2025 full-year result was $599.7 million, down 13.28% from the prior year.
• Assets Average for Q1 2026 stood at $580.2 million, up from $571.9 million in the prior quarter.
• The five-year high for Assets Average was $810.9 million in Q4 2023, with the low at $527.8 million in Q3 2024.
• Historically, Assets Average has averaged $670.6 million across 5 years, with a median of $699.4 million in 2022.
• Annual changes were most pronounced in 2022 — Assets Average increased 17.03% — and 2024, when it tumbled 32.74%.
• Travere Therapeutics' Assets Average stood at $699.4 million in 2022, then gained by 15.94% to $810.9 million in 2023, then plunged by 32.26% to $549.3 million in 2024, then advanced by 4.12% to $571.9 million in 2025, then climbed by 1.45% to $580.2 million in 2026.
• The last three Assets Average figures came in at $580.2 million (Q1 2026), $571.9 million (Q4 2025), and $546.9 million (Q3 2025), per Business Quant data.